

CORRESPONDENCE ON

Demographic and clinical features of pediatric vasculitis: a single-center study

Shahid F¹, Arif H¹, Rafiq Y¹, Ansari Z¹

Dear Editor,

We have ardently reviewed the article by Trindade TS *et al*, titled “Demographic and clinical features of pediatric vasculitis: a single-center study”¹. The paper was brief yet beautifully articulated, and we appreciate the author for delivering an outstanding work that enriched our understanding.

Although we agree with the article’s results and conclusion that each particular vasculitis examined displays distinct primary symptoms, common signs, and symptoms overlap across various vasculitides. Yet, we must acknowledge some additional points in this article that could contribute to reinforcing the validity of the study’s conclusions.

Firstly, the article’s reliance on a single-center study design raises concerns about its potentially limited external applicability. Such studies typically involve smaller sample sizes due to the restriction of recruiting participants from just one location, which can increase the risk of confounding variables influencing the outcomes². Additionally, single-center studies may need more diversity, selection bias, and reduced expertise, leading to diminished statistical power for the study’s findings. Secondly, it is essential to note that the study’s sample size was relatively small, consisting of only 138 participants. This limited number of participants might compromise the reliability of the results and make it challenging to generalize the findings to a larger population. In a research conducted by J Int Med Res, they examined 1896 pediatric patients, signifying a substantial number of participants³. If the sample size had been even larger, the outcomes might have yielded a more all-encompassing insight into the studied population. This would have facilitated more dependable statistical interpretations and extended the applicability of the findings to a broader group. Lastly, there was no data regarding anti-TNF alpha agents for treating Takayasu arteritis, immunosuppressants, and

radiation therapy for treating polyarteritis nodosa. These therapy options were considered in a study by Morishita⁴. As a result, these therapy options have the potential to enhance the prognosis for individuals with Takayasu arteritis and polyarteritis nodosa.

In conclusion, our letter to the editor highlights the importance of ongoing research and awareness in the field of pediatric vasculitis. We encourage continued dialogue and investigations to improve outcomes for affected children.

REFERENCES

1. Trindade TS, Morais CG, Maia A, Rodrigues M, Brito I. Demographic and clinical features of pediatric vasculitis: a single-center study. *ARP Rheumatology* 2023;2(1):30–40. Available from: <https://pubmed.ncbi.nlm.nih.gov/36739540/>
2. Bafeta A, Dechartres A, Trinquart L, Yavchitz A, Boutron I, Ravaud P. Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. *BMJ* 2012;14:344. Available from: <https://www.bmj.com/content/344/bmj.e813>
3. Mao Y, Yin L, Xia H, Huang H, Zhou Z, Chen T, et al. Incidence and clinical features of pediatric vasculitis in Eastern China: 14-year retrospective study, 1999–2013. *Journal of International Medical Research*. 2016 Mar 23;44(3):710–7. <https://doi.org/10.1177/0300060515621446>
4. Morishita K, Brown K, Cabral D. Pediatric vasculitis. *Current Opinion in Rheumatology*. 2015 Sep;27(5):493–9. <https://doi.org/10.1097/BOR.0000000000000203>

¹ Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan

Submitted: 11/09/2023

Accepted: 18/09/2023

Correspondence to: Fatima Shahid

E-mail: fatima11082k@gmail.com